Peptide comparison
They meet on one specific ground: experimental models of intestinal inflammation. But they arrive there from different places. KPV is the tail end of the hormone α-MSH and acts on inflammatory signalling; BPC-157 is a synthetic peptide of gastric origin associated with mucosal repair.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| KPV | BPC-157 | |
|---|---|---|
| Structure | Tripeptide Lys-Pro-Val | Synthetic pentadecapeptide |
| Origin | C-terminal end of α-MSH | Partial sequence of a gastric protein |
| Described mechanism | Inhibition of the NF-κB inflammatory pathway | Angiogenesis, nitric oxide, mucosal protection |
| Entry into intestinal cells | PepT1 peptide transporter | Not specifically described |
| Main models | Experimental colitis, skin inflammation | Ulcers, colitis, fistulas and musculoskeletal injuries |
| Maturity of the evidence | Preclinical | Preclinical |
KPV keeps the anti-inflammatory activity of α-MSH without its effects on pigmentation. In cell and animal models it reduces the activation of NF-κB, a central switch of inflammation, and it has been described as entering intestinal cells through the PepT1 transporter, whose expression increases in inflamed mucosa. That has prompted studies with oral formulations targeted at the colon.
BPC-157 has been studied in a wider range of gastrointestinal injury models (ulcers, fistulas, colitis) with proposed mechanisms linked to blood vessel formation and nitric oxide. In both cases the evidence is preclinical. Their combination in the KLOW blend reflects the idea of adding an anti-inflammatory pathway to other repair pathways.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
A tripeptide (lysine-proline-valine) corresponding to the tail end of the hormone α-MSH. It is studied for its anti-inflammatory activity, mainly in models of intestinal inflammation.
No. KPV is associated with inhibition of NF-κB inflammatory signalling; BPC-157 with repair mechanisms such as angiogenesis and nitric oxide.
The evidence for both is mainly preclinical, in cell cultures and animal models.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →